Media coverage about vTv Therapeutics (NASDAQ:VTVT) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. vTv Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.6616812619373 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news stories that may have effected Accern’s scoring:

VTVT has been the topic of a number of research reports. Zacks Investment Research cut shares of vTv Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, April 27th. HC Wainwright set a $13.00 target price on shares of vTv Therapeutics and gave the company a “buy” rating in a report on Thursday, May 4th. Finally, Canaccord Genuity restated a “buy” rating and set a $15.00 target price on shares of vTv Therapeutics in a report on Friday. Five investment analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $14.15.

Shares of vTv Therapeutics (VTVT) remained flat at $4.04 during trading on Tuesday. The stock had a trading volume of 31,517 shares. vTv Therapeutics has a 12 month low of $4.00 and a 12 month high of $7.50. The stock’s 50-day moving average is $4.67 and its 200 day moving average is $5.33. The stock’s market cap is $132.56 million.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.02. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.19 million. On average, equities research analysts expect that vTv Therapeutics will post ($1.08) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at

About vTv Therapeutics

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Insider Buying and Selling by Quarter for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with's FREE daily email newsletter.